Rayonier Advanced Materials (RYAM) Q4 2025 earnings review
Stabilizing Core Operations, But Heavy Cash Burn Requires Immediate Action
2025 was a brutal transition year for RYAM. While Q4 revenue of $417M stabilized sequentially and nearly matched prior year levels, the full-year picture reveals deep wounds: Adjusted EBITDA collapsed 40% to $133M, and Adjusted Free Cash Flow reversed sharply to negative $88M. The core Cellulose Specialties business successfully pushed price increases, but non-core segments like Paperboard fell off a cliff due to new competitive capacity. Incoming CEO Scott Sutton is forcefully pivoting the narrative for 2026 away from growth promises to strict operational discipline: cutting CapEx, tightening working capital, and demanding positive free cash flow. While the long-term biomaterials story remains intact, 2026 is squarely about surviving the balance sheet pressures and recapturing lost pricing power.
🐂 Bull Case
Cellulose Specialties average sales price increased 7% YoY in Q4. Management successfully executed its 'value over volume' strategy, reclaiming margins lost to inflation.
After operational disasters and tariff shocks in early 2025 (Q1 EBITDA of $17M), the company has demonstrated accelerating sequential earnings recovery, reaching $46M in Q4.
🐻 Bear Case
The company consumed $88M in Adjusted Free Cash Flow in FY25, pushing net secured leverage to 3.9x. Interest expenses alone drained $98M, leaving no margin for operational error.
Paperboard and High-Yield Pulp generated operating losses in Q4. With the Paperboard divestiture delayed by trade uncertainty, these assets continue to bleed cash and management attention.
⚖️ Verdict: 🔴
Bearish. While sequential EBITDA recovery is commendable, a negative $88M free cash flow profile and 3.9x leverage ratio create structural overhangs. The 2026 plan correctly targets cash preservation, but volume pressures from aggressive pricing actions pose near-term execution risks.
Key Themes
Cellulose Specialties Executing on Price Reset
The crown jewel segment is flexing its pricing muscle. Q4 Cellulose Specialties sales grew 2% YoY to $249M, entirely driven by a 7% increase in average sales price ($1,875/ton) that offset a 4% volume decline. Management is accelerating this 'significant price reset' to recapture historic inflation costs, though they caution this will temporarily pressure volumes early in 2026 as customers adjust inventory.
Paperboard Collapse Accelerating
The Paperboard segment is decelerating rapidly. Q4 sales collapsed 27% YoY to $44M, battered by a 19% volume drop and a 9% price decline due to new U.S. capacity pressures. Operating results reversed from a $4M profit last year to a $1M loss. With the planned divestiture of this asset stalled by USMCA trade uncertainty, RYAM is forced to implement market-driven downtime, further pressuring fixed cost absorption.
Crippling Cash Flow and Debt Service
RYAM is trapped in a vicious cycle of high debt service and poor working capital conversion. FY25 cash provided by operations plummeted to $24M (from $203M in FY24), while interest expense spiked to $98M. Reversing this cash burn is the exclusive priority for 2026, requiring harsh CapEx cuts and working capital liquidation to defend the 3.9x leverage ratio against a 5.0x covenant.
Biomaterials Offering a Growth Lifeline
The Biomaterials segment remains a bright spot, accelerating with Q4 sales up 25% YoY to $10M. Growth was driven by the ramp-up of the new bioethanol facility and resumed lignosulfonate powder production in France. While currently a small piece of the revenue pie, management's strategic focus on these high-ROI (target >30%) projects represents the clearest path to margin expansion without requiring massive new equity injections.
Other KPIs
Decelerating sharply from $222M in FY24. The massive drop was front-loaded in H1 2025 due to operational outages, strikes, and Chinese tariffs. The Q4 result of $46M shows the business is stabilizing at a ~$180M run-rate, but still well below historic highs.
Down 10% YoY from $1.630B. The decline was largely driven by a massive 20% drop in overall sales volumes (excluding Biomaterials), compounded by intentional downtime in Paperboard and High-Yield pulp to manage inventory.
Stable quarter-over-quarter, comprising $75M in cash and $82M in borrowing capacity. However, this is significantly lower than the $276M liquidity reported at the end of FY24, reflecting the heavy operational cash drain experienced throughout 2025.
Guidance
Reversing. Management has drawn a hard line in the sand to turn FY25's $(88)M burn into positive generation. This will require massive working capital improvements and a strict reduction in CapEx prioritizing only essential maintenance.
Accelerating. While no explicit numerical range was provided, management committed to YoY EBITDA improvement across 'every business', implying a target comfortably above the $133M achieved in FY25.
Key Questions
Early 2026 Volume Pressure
You noted that Cellulose Specialties volumes will be pressured early in the year as customers adjust to your pricing actions. Are you seeing order cancellations, or just deferrals, and what is the expected timeline for volume normalization?
CapEx Reductions
The mandate to generate positive free cash flow relies heavily on reducing CapEx relative to 2025's $116M spend. What is the absolute floor for maintenance CapEx to keep these plants running safely, given the costly equipment failures experienced in early 2025?
Paperboard Strategy
With Paperboard sales down 27% and operating margins flipping negative due to new U.S. capacity, and divestiture stalled by trade talks, how long are you willing to absorb cash losses here before taking more drastic restructuring actions?